CLINICAL_TRIALS trial_result · 2020-02-10

Clinical Trial Update: A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) [Phase 3]

Phase 3 clinical trial ENLIGHTEN-2 evaluating ALKS 3831 in adults with schizophrenia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Alkermes, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2020-02-10